CoChat

Blood safety strategies for human T‐cell lymphotropic virus in Europe

Laperche, S., Worms, B., Pillonel, J., for the European Network of Transfusion Medecine Societies and the Steering Committee of the Epidemiological Surveillance of Blood Donors in France · 2009 · Vox Sanguinis
Cited by 75

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background To prevent the blood transmission of human T‐cell lymphotropic virus (HTLV), different countries have introduced anti‐HTLV blood screening. Furthermore, leucoreduction of blood components has been implemented to preclude the transmission of infectious agents present in white blood cells. Study Design and Methods To evaluate the current European strategies adopted to ensure the blood safety for HTLV, a European investigation spanning a period from 2003 to 2008 was carried out. Results In 2003, of the 23 included countries, 11 performed anti‐HTLV screening, four of which (Scandinavian countries) only did it on first‐time donors. Norway and Finland stopped it in 2007 and 2008, respectively. Two groups may be defined according to increasing prevalence rates per 10 000 donations in first‐time donors: Scandinavia and Ireland (0 to 0·17), France, the Netherlands and UK (0·45 to 0·48); Romania was clearly apart from all other participating countries (5·33). HTLV‐positive donors (88·6%) either come from endemic areas (82·3%) or declare to have a sexual partner coming from endemic areas (6·3%). Of the 283 HTLV‐positive donations that could be characterized, 6·6% were HTLV‐II. Fourteen of 22 countries currently use systematic leucoreduction, at least in cellular blood components. Six countries perform both universal anti‐HTLV screening and blood cell leucoreduction. Conclusion The implementation of leucoreduction did not modify the blood HTLV‐screening policy, except for Norway and Finland. Several screening strategies in low endemic countries performing leucoreduction were discussed. However, the withdrawal of anti‐HTLV screening should be decided after assessing the remaining HTLV transfusion risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1423-0410.2008.01136.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 75

Metadata

Authors
Laperche, S., Worms, B., Pillonel, J., & for the European Network of Transfusion Medecine Societies and the Steering Committee of the Epidemiological Surveillance of Blood Donors in France
Venue
Vox Sanguinis
Publisher
Wiley
Published
2009-01-12
Volume
96
Issue
2
Pages
104-110
ISSN
  • 0042-9007 (ISSN-L)
  • 1423-0410
OpenAlex
W1988050350
Cited by
75
References
2
FWCI
9.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood safety strategies for human T‐cell lymphotropic virus in Europe. https://app.cochat.ai/papers/10.1111/j.1423-0410.2008.01136.x
The paper
Laperche, S., Worms, B., Pillonel, J., & for the European Network of Transfusion Medecine Societies and the Steering Committee of the Epidemiological Surveillance of Blood Donors in France. (2009). Blood safety strategies for human T‐cell lymphotropic virus in Europe. Vox Sanguinis. https://doi.org/10.1111/j.1423-0410.2008.01136.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.